Sunday 9 September 2018

MCQ

QUESTION 1 In a postmenopausal woman with abnormal vaginal bleeding who is not receiving hormone replacement therapy, which of the following endometrial thickness cutoff criteria is used to optimize accuracy for detecting cancer?
 A. ≥ 4 mm.
 B. ≥ 5 mm.
 C. ≥ 6 mm.
D. ≥ 7 mm.
E. ≥ 8 mm.

QUESTION 2 In a postmenopausal woman with abnormal vaginal bleeding who is undergoing hormone replacement therapy, which of the following endometrial thickness cutoff criteria is used to optimize accuracy for detecting cancer?
 A. ≥ 4 mm.
 B. ≥ 5 mm.
C. ≥ 6 mm.
D. ≥ 7 mm.
 E. ≥ 8 mm.

Monday 4 June 2018

PERFUSION IMAGING ---BASICS

-------Perfusion magnetic resonance (MR) imaging techniques are widely used in the clinical work-up of brain tumors because of their ability to help quantify tumor microvessel proliferation and permeability and thus to measure changes associated with neoangiogenesis, which correlate with tumor malignancy. 

-----Dynamic susceptibility contrast (DSC) MR imaging  has been extensively explored for glioma grading , for prognostic assessment , and for differentiating between recurrent tumor and posttreatment changes . 

-----Dynamic contrast material–enhanced (DCE) MR imaging has been recently introduced in the preoperative assessment and follow-up of brain tumors. 

------The DCE signal intensity– time curve reflects a combination of tissue perfusion, microvessel permeability, and extravascular-extracellular space , thus allowing for a multiparametric characterization of tumor microvasculature. 

------The advantages of DCE over DSC are fewer susceptibility artifacts and the quantification of blood-brain barrier (BBB) integrity; indeed, the main interest for DCEderived metrics was initially focused on the volume transfer constant (Ktrans), a permeability marker correlating with BBB disruption and malignancy . 



----The advantage of DSC over DCE is better temporal resolution, allowing better estimation of blood volume. 

PRECISION MEDICINE/RADIOMICS/RADIOGENOMICS



----Precision medicine is medicine optimized to the genotypic and phenotypic characteristics of an individual and, when present, his or her disease. It has a host of targets, including genes and their transcripts, proteins, and metabolites. 

----Studying precision medicine involves a systems biology approach that integrates mathematical modeling and biology genomics, transcriptomics, proteomics, and metabolomics. 

----Moreover, precision medicine must consider not only the relatively static genetic codes of individuals, but also the dynamic and heterogeneous genetic codes of cancers. Thus, precision medicine relies not only on discovering identifiable targets for treatment and surveillance modification, but also on reliable, noninvasive methods of identifying changes in these targets over time. 

---Imaging via radiomics and radiogenomics is poised for a central role. 

-----Radiomics, which extracts large volumes of quantitative data from digital images and amalgamates these together with clinical and patient data into searchable shared databases, potentiates radiogenomics, which is the combination of genetic and radiomic data.

----- Radiogenomics may provide voxel-by-voxel genetic information for a complete, heterogeneous tumor or, in the setting of metastatic disease, set of tumors and thereby guide tailored therapy.

 -----Radiogenomics may also quantify lesion characteristics, to better differentiate between benign and malignant entities, and patient characteristics, to better stratify patients according to risk for disease, thereby allowing for more precise imaging and screening. 
REF --RADIOLOGY

Saturday 2 June 2018

TELE -BILI-PAQUE


Q1..All are true regarding Telepaque and Bilipaque except
a.bilopaque is better choice than Telepaque in patients with enterrupted enterohepatic circulation
b.Telepaque is more lipid –soluble than Bilopaque
c.peak contrast concentration occurs after approx.10 hrs after Bilopaque  ingestion
d.the usual dose of Telepaque is 6 tabs after evening meal
e.patients must take fat after ingetion of Telepaque


ANS.---e
Patients must not take anything except water after ingestion of Telepaque


Q2..All are causes of non visualisation of  the gall bladder during oral cholecystography except
a.esophageal /gastric/small intestinal obstruction
b.Crohn disease
c.disruption of renal circulation
d.hepatic dysfunction
e.acute/chronic cholecystitis
ANS.---c
Disruption of entero-hepatic circulation is one of the cause of non –visualisation of gall bladder

Thursday 3 May 2018

GATEWAY TO LIVER ( PORTA)


Q.All are true regarding anatomy of hepatobiliary system except

a.The porta is fat filled space

b.Bile duct act as landmark for the anterolateral margin of 

pancreatic head

c.The intraduodenal segment of bile duct is approx 1 to 2cm

d.Spiral valves of Heister is located in the neck of gall bladder

e.Phgrygian cap  is due to folding of gall bladder fundus on itself

ANS.---b

Bile duct act as landmark for the postero-lateral margin of 

pancreatic head.The gastroduodenal artery acts as landmark of 

anterolateral margin of the pancreatic head

Wednesday 11 April 2018

First step in fetal echo----visceral situs

                    Visceral situs ( determination of laterality of fetal organs)


----first step in fetal echo ---why? allow for accurate determination of atrial and
ventricular  situs
----Three types of visceral situs
      1.situs solitus---normal arrangement of vessels and organs within the body
      2.situs inversus---mirror image arrangement of organs and vessels  to situs solitus(.01% of population ),slight increase in complex CHD
      3.situs ambiguus(heterotaxy) ,incidence --1per 10,000 infants,commonly associated with complex CHD
Two types of heterotaxy
a.Right isomerism( asplenia)---both sides of body show the right morphology
b.Left isomerism( polysplenia)--both sides of body show the left morphology

SITUS SOLITUS
                                        RIGHT SIDE                                 LEFT SIDE
                                    Morphologic right atrium                   Morphologic left atrium
                                     major hepatic veins                            Stomach
                                      IVC                                                    Descending aorta
                                  short eparterial bronchus                      Long hyparterial bronchus


    TECHNIQUE

1.Locate  the fetal head within the uterus and determine the presenting part ( cephalic,breech etc)
2.Determine the fetal lie within the uterus by obtaining the saggital view of the fetal spine ( longitudinal ---when fetal spine is parallel to maternal spine /transverse---when fetal spine is perpendicular to the maternal spine / oblique lie ---when the fetal  spine is oblique to the maternal spine )
3.Determine the location of fetal left side with regard to maternal abdomen ( anterior/posterior /right lateral/left lateral )
4.Obtain the transverse view of the fetal abdomen by rotating the transducer  90 degrees from the saggittal view of the lower thoracic spine .
The fetal stomach is imaged in the left side of the abdomen,the descending aorta is posterior to the left and IVC is anterior to the right .
Now slide the transducer toward the fetal chest to obtain the four- chamber view of the heart .
The apex of the heart  points toward the left side of the fetal chest .

Determining that the stomach ,descending aorta and the cardiac apex are located on the fetal left side and the IVC is located on the right side establishes normal visceral situs
There are other methods to determine the visceral situs like Cordes et al and right and left hand rule of Bronshtein

Monday 2 April 2018

FETAL ECH---FOUR CHAMBER VIEW


--Fetal echo  detects majority of structural cardiac abnormalities.
---most neonates born with CHD have no preidentified risk factors. 
---prenatal detection rates of isolated CHD have remained below 50% in the general population
---Four chamber view and the outflow tracts are used for prenatal detection of CHD
---Outflow tracts view of fetal heart show better detection of CHD when compared to the four chamber view 
---Nuchal translucency ( 10 -14 weeks) greater than or equal to 3,55 mm is an indication for fetal echo

Criteria of normal four chamber view of heart
1.normal fetal situs
2.normal size in relation to chest
3.the two atria a---equal in size and the flap of the foramen ovale is seen in the left atrium
4.the venticles are equal in size and contactility ,moderator band in the apex of right ventricle 
5.atrial and ventricular septae are normal appearing
6.the AV valves are normal appearing .the tricuspid valve appears to insert more apically on the ventricular septum

Image result for four chambers of heart echo

CARDIAC ABNORMALITIES associated with abnormal four-chamber view of the heart 

1.mitral/aortic atresia
2.tricuspid /pulmonary atresia 
3.Ebstein anomaly /tricuspid valve dysplasia
4.AV septal defect
5.large VSD
6.single ventricle (double inlet)
7/severe/aortic /pulmonary stenosis
8.severe coarctation of aorta
9.TAPVC
10.cardiomyopathies /tumour

 CARDIAC ABNORMALITIES associated with NORMAL  four-chamber view of the heart 
1.TOF
2.TGA
3.double outlet right ventricle 
4.small VSD
5.common arterial trunk
6.aortic arch abnormalities 



Saturday 31 March 2018

RISK FACTORS OF CONGENITAL HEART DISEASE

RISK FACTORS OF CONGENITAL HEART DISEASE

FETAL


---Chromosomal abnormalities
---extracardiac anatomic abnormalities ( nonimmune hydrops ,single umblical artery ,renal agenisis omphalocoele  etc) 
---fetal cardiac arrhythmia
---suspected cardiac anomaly on routine usg
---thickened nuchal translucency(>/-3.5mm)
---monochorionic plancentation

MATERNAL

----Family history of CHD
----maternal metabolic disorder ( diabetes ,PKU)
---maternal teratogen exposure (lthium,hydantoin,valproic acid ,ethanol,isotretinoin,ACE inhibitors ,SSRIs)
---pregnancy of assisted reproduction
---maternal obesity 

Sunday 11 February 2018

CT NO OF LIVER


6         Q.Which cause significant increase of CT no of
           liver

      a.fatty liver
  b.fibrosis
  c.increased cu content
  d.gycogen
  e.none

       ANS---e